Literature DB >> 32609322

Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017.

Selin Tokez1, Marlies Wakkee1, Marieke Louwman2, Eline Noels1,2, Tamar Nijsten1, Loes Hollestein1,2.   

Abstract

Importance: The incidence rates of keratinocyte cancer are increasing globally; however, the incidence rates of cutaneous squamous cell carcinoma (cSCC) in situ and the risk of developing subsequent invasive cSCC remain unknown. Objective: To estimate annual population-based age-standardized incidence rates of histopathologically confirmed cSCC in situ stratified by sex, age, and body site and to assess the risk of developing invasive cSCC among patients with cSCC in situ compared with the general population. Design, Setting, and Participants: This nationwide epidemiological population-based cohort study used cancer registry data to identify all patients with a first incident of histopathologically confirmed cSCC in situ between January 1, 1989, and December 31, 2017. In addition, all patients with cSCC in situ who subsequently had a first incident of invasive cSCC were identified up to June 11, 2019. Data were analyzed between March 18 and November 12, 2019. Main Outcomes and Measures: Age-standardized incidence rates per year for cSCC in situ, standardized to the 2013 edition of the European Standard Population, were calculated by sex, age, and body site. Cumulative risks, standardized incidence ratios, and absolute excess risks were calculated to assess the risk of invasive cSCC in patients with cSCC in situ compared with the general population.
Results: In this population-based cohort study of 88 754 patients with a first incident of cSCC in situ between January 1, 1989, and December 31, 2017, 58.8% were women; the median age was 75 years (interquartile range [IQR], 67-82 years) for women and 73 years (IQR, 65-80 years) for men. Increasing incidence rates were observed, with the highest incidence rates in 2017 among women in general (71.7 cases per 100 000 person-years) and among men 80 years and older (540.9 cases per 100 000 person-years). The most common body site among women was the face (15.9 cases per 100 000 person-years) and among men was the scalp and/or neck (12.3 cases per 100 000 person-years). After 5 years of follow-up, among patients with cSCC in situ, the cumulative risk of developing an invasive cSCC at any anatomic location was 11.7% (95% CI, 11.6%-11.9%) in men and 6.9% (95% CI, 6.8%-7.0%) in women (P < .001). The standardized incidence ratio was highest in the first year of follow-up among both men (16.6; 95% CI, 15.7-17.5) and women (15.1; 95% CI, 14.2-16.1). Conclusions and Relevance: This study reports the first nationwide incidence rates of cSCC in situ to date. The increasing incidence rates of cSCC in situ and the high risk of developing invasive cSCC among patients with cSCC in situ may increase the health care burden associated with precursors of keratinocyte cancer and highlight the need to include cutaneous skin cancer precursor lesions when exploring policies to address skin cancer care.

Entities:  

Mesh:

Year:  2020        PMID: 32609322      PMCID: PMC7330830          DOI: 10.1001/jamadermatol.2020.1988

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  34 in total

1.  Guidelines for management of Bowen's disease. British Association of Dermatologists.

Authors:  N H Cox; D J Eedy; C A Morton
Journal:  Br J Dermatol       Date:  1999-10       Impact factor: 9.302

2.  Bowen's Disease: a four-year retrospective review of epidemiology and treatment at a university center.

Authors:  Jason P Hansen; Ashley L Drake; Hobart W Walling
Journal:  Dermatol Surg       Date:  2008-07       Impact factor: 3.398

3.  Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989-2008.

Authors:  L M Hollestein; E de Vries; T Nijsten
Journal:  Eur J Cancer       Date:  2012-02-16       Impact factor: 9.162

4.  Trends in the Incidence of Bowen Disease Based on a Single-Center Study in the Netherlands.

Authors:  Maud H E Jansen; Hilal Özhan-Hasan; Patty J Nelemans; Veronique J Winnepenninckx; Klara Mosterd
Journal:  Dermatol Surg       Date:  2019-11       Impact factor: 3.398

5.  Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients.

Authors:  A B Jaeger; A Gramkow; H Hjalgrim; M Melbye; M Frisch
Journal:  Arch Dermatol       Date:  1999-07

6.  Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions.

Authors:  M Trakatelli; C Ulrich; V del Marmol; S Euvrard; S Euvard; E Stockfleth; D Abeni
Journal:  Br J Dermatol       Date:  2007-05       Impact factor: 9.302

7.  Epidemiology of Lentigo Maligna and Lentigo Maligna Melanoma in the Netherlands, 1989-2013.

Authors:  Karin Greveling; Marlies Wakkee; Tamar Nijsten; Renate R van den Bos; Loes M Hollestein
Journal:  J Invest Dermatol       Date:  2016-06-24       Impact factor: 8.551

8.  The capture-recapture method for estimation of cancer registry completeness: a useful tool?

Authors:  L J Schouten; H Straatman; L A Kiemeney; C H Gimbrère; A L Verbeek
Journal:  Int J Epidemiol       Date:  1994-12       Impact factor: 7.196

9.  The subsequent risk of internal cancer with Bowen's disease. A population-based study.

Authors:  C G Chute; T Y Chuang; E J Bergstralh; W P Su
Journal:  JAMA       Date:  1991-08-14       Impact factor: 56.272

10.  Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive.

Authors:  M Casparie; A T M G Tiebosch; G Burger; H Blauwgeers; A van de Pol; J H J M van Krieken; G A Meijer
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

View more
  5 in total

1.  Environmental effects of stratospheric ozone depletion, UV radiation, and interactions with climate change: UNEP Environmental Effects Assessment Panel, Update 2020.

Authors:  R E Neale; P W Barnes; T M Robson; P J Neale; C E Williamson; R G Zepp; S R Wilson; S Madronich; A L Andrady; A M Heikkilä; G H Bernhard; A F Bais; P J Aucamp; A T Banaszak; J F Bornman; L S Bruckman; S N Byrne; B Foereid; D-P Häder; L M Hollestein; W-C Hou; S Hylander; M A K Jansen; A R Klekociuk; J B Liley; J Longstreth; R M Lucas; J Martinez-Abaigar; K McNeill; C M Olsen; K K Pandey; L E Rhodes; S A Robinson; K C Rose; T Schikowski; K R Solomon; B Sulzberger; J E Ukpebor; Q-W Wang; S-Å Wängberg; C C White; S Yazar; A R Young; P J Young; L Zhu; M Zhu
Journal:  Photochem Photobiol Sci       Date:  2021-01-20       Impact factor: 4.328

Review 2.  Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges.

Authors:  Tuba M Ansary; M D Razib Hossain; Mayumi Komine; Mamitaro Ohtsuki
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

3.  Evaluation of a Deep Learning Approach to Differentiate Bowen's Disease and Seborrheic Keratosis.

Authors:  Philipp Jansen; Daniel Otero Baguer; Nicole Duschner; Jean Le'Clerc Arrastia; Maximilian Schmidt; Bettina Wiepjes; Dirk Schadendorf; Eva Hadaschik; Peter Maass; Jörg Schaller; Klaus Georg Griewank
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

4.  Identification and validation of four photodynamic therapy related genes inhibiting MAPK and inducing cell cycle alteration in squamous cell carcinoma.

Authors:  Yingchao Zhao; Jianxiang Dong; Yuxuan Liao; Hongyi Wang; Dawei Zhou; Jian Kang; Xiang Chen
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

Review 5.  The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts.

Authors:  Ignazio Stanganelli; Francesco Spagnolo; Giuseppe Argenziano; Paolo A Ascierto; Franco Bassetto; Paolo Bossi; Vittorio Donato; Daniela Massi; Cesare Massone; Roberto Patuzzo; Giovanni Pellacani; Pietro Quaglino; Paola Queirolo; Iris Zalaudek; Giuseppe Palmieri
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.